30.30
0.60 (2.02%)
| Previous Close | 29.70 |
| Open | 29.60 |
| Volume | 1,909,000 |
| Avg. Volume (3M) | 1,526,167 |
| Market Cap | 8,404,794,880 |
| Price / Sales | 88.78 |
| Price / Book | 2.92 |
| 52 Weeks Range | |
| Earnings Date | 27 Aug 2024 |
| Operating Margin (TTM) | -719.51% |
| Diluted EPS (TTM) | -3.05 |
| Quarterly Revenue Growth (YOY) | -83.30% |
| Total Debt/Equity (MRQ) | 28.49% |
| Current Ratio (MRQ) | 4.98 |
| Operating Cash Flow (TTM) | -709.18 M |
| Levered Free Cash Flow (TTM) | -658.76 M |
| Return on Assets (TTM) | -13.19% |
| Return on Equity (TTM) | -24.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | KEYMED BIO-B | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Average | 0.00 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| KEYMED BIO-B | 8 B | - | - | 2.92 |
| 3SBIO | 15 B | 3.86% | 8.67 | 0.910 |
| HAOHAI BIOTEC | 15 B | 4.37% | 14.16 | 0.960 |
| AKESO | 55 B | - | - | 9.50 |
| INNOVENT BIO | 53 B | - | - | 4.54 |
| BEIGENE | 195 B | - | - | 6.93 |
|
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Value |
| % Held by Insiders | 32.62% |
| % Held by Institutions | 29.45% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |